血液系统恶性肿瘤危重症患者的严重出血事件
该单中心回顾性研究纳入2007—2018年12年间1012例需非计划入ICU的成人血液系统恶性肿瘤患者,主要诊断为淋巴瘤(42.9%)和白血病或骨髓增生异常综合征(26.3%)。主要终点为入ICU 24小时后发生的ICU获得性严重出血事件(世界卫生组织分级3或4级),发生率为10.8%,出血主要来源为胃肠道(40.3%)。多因素分析显示,入ICU时存在原发岀血事件、慢性肾病、非血小板SOFA评分升高及凝血酶原时间延长是ICU获得性严重出血的独立预测因素。发生出血者ICU住院时间延长,ICU病死率55% vs 18.3%、住院病死率65.7% vs 33.1%,均显著增高。
要点
- 1012例血液系统恶性肿瘤危重症患者中,109例(10.8%)发生ICU获得性严重出血(WHO分级3或4级),中位发生时间为入ICU后3.0天[1.0-7.0]。
- 出血主要来源为胃肠道(n=44,40.3%)。
- 发生ICU获得性严重出血者ICU病死率55% vs 未出血者18.3%,住院病死率65.7% vs 33.1%(均p<0.001)。
- 多因素分析独立预测因素:入ICU时原发岀血事件(CSH 4.17 [2.71-6.43],p<0.001)、慢性肾病(CSH 2.00 [1.19-3.31],p=0.008)、非血小板SOFA评分每增加1分(CSH 1.06 [1.01-1.11],p=0.02)、事件前一日凝血酶原时间每延长5%(CSH 0.90 [0.85-0.96],p=0.001)。
- 作者认为,所识别的出血危险因素可能促使更密切监测或采取预防措施。
适用人群与场景
- 单中心回顾性研究纳入2007—2018年12年间所有有血液系统恶性肿瘤病史、需非计划入ICU的成人患者。
- 主要诊断为淋巴瘤(n=434,42.9%)和白血病或骨髓增生异常综合征(n=266,26.3%);多数患者为近期诊断(n=340,33.6%),59.7%(n=604)在最近3个月内接受抗肿瘤治疗。
- 入ICU主要原因:感染(n=479,47.3%),原发岀血(n=99,10%)。
诊断标准与关键阈值
- ICU获得性严重出血事件定义为入ICU 24小时后发生的世界卫生组织(WHO)分级3级或4级出血。
红旗征与不能漏的情况
- 入ICU时存在原发岀血事件是ICU获得性严重出血的独立预测因素(CSH 4.17 [2.71-6.43],p<0.001)。
- 慢性肾病(CSH 2.00 [1.19-3.31],p=0.008)、非血小板SOFA评分升高(每分CSH 1.06 [1.01-1.11],p=0.02)及事件前一日凝血酶原时间延长(每5% CSH 0.90 [0.85-0.96],p=0.001)与ICU获得性严重出血独立相关。
研究设计与关键结果
- 研究类型:单中心回顾性研究;样本量1012例;人群:有血液系统恶性肿瘤病史、需非计划入ICU的成人患者;时间跨度2007—2018年。
- 主要终点:ICU获得性严重出血事件发生于109例(10.8%),中位发生时间入ICU后3.0天[1.0-7.0];出血主要来源为胃肠道(n=44,40.3%)。
- 发生ICU获得性严重出血者ICU住院时间9.0天[1.0-6.0] vs 未出血者3.0天[3.5-15.0],p<0.001;ICU病死率55% vs 18.3%,住院病死率65.7% vs 33.1%,均p<0.001。
- 多因素分析独立预测因素:慢性肾病CSH 2.00 [1.19-3.31],p=0.008;入ICU时原发岀血事件CSH 4.17 [2.71-6.43],p<0.001;非血小板SOFA评分每增加1分CSH 1.06 [1.01-1.11],p=0.02;事件前一日凝血酶原时间每延长5% CSH 0.90 [0.85-0.96],p=0.001。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,所识别的出血危险因素(入ICU时原发岀血、慢性肾病、非血小板SOFA评分升高、凝血酶原时间延长)可能促使更密切监测或采取预防措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Bleeding events are common complications in critically ill patients with haematological malignancies. The objective of this study was to assess the incidence and identify determinants of ICU-acquired severe bleeding events in critically ill patients with haematological malignancies. We conducted a single-center retrospective study including all adult patients with a history of haematological malignancy requiring unplanned ICU admission over a 12-year period (2007-2018). The primary endpoint was the occurrence of ICU-acquired (i.e. after the first 24 h in the ICU) severe bleeding events, as defined as grades 3 or 4 of the World Health Organization classification.
RESULTS: A total of 1012 patients were analysed, mainly with a diagnosis of lymphoma (n = 434, 42.9%) and leukaemia or myelodysplastic syndrome (n = 266, 26.3%). Most patients were recently diagnosed (n = 340, 33.6%) and under active cancer treatment within the last 3 months (n = 604, 59.7%). The main cause for admission was infection (n = 479, 47.3%), but a significant proportion of patients were admitted for a primary haemorrhage (n = 99, 10%). ICU-acquired severe bleeding events occurred in 109 (10.8%) patients after 3.0 days [1.0-7.0] in the ICU. The main source of bleeding was the gastrointestinal tract (n = 44, 40.3%). Patients experiencing an ICU-acquired severe bleeding event displayed prolonged in-ICU length of stay (9.0 days [1.0-6.0] vs. 3.0 [3.5-15.0] in non-bleeding patients, p < 0.001) and worsened outcomes with increased in-ICU and in-hospital mortality rates (55% vs. 18.3% and 65.7% vs. 33.1%, respectively, p < 0.001). In multivariate analysis, independent predictors of ICU-acquired severe bleeding events were chronic kidney disease (cause-specific hazard 2.00 [1.19-3.31], p = 0.008), a primary bleeding event present at the time of ICU admission (CSH 4.17 [2.71-6.43], p < 0.001), non-platelet SOFA score (CSH per point increase 1.06 [1.01-1.11], p = 0.02) and prolonged prothrombin time (CSH per 5-percent increase 0.90 [0.85-0.96], p = 0.001) on the day prior to the event of interest.
CONCLUSIONS: Major bleeding events are common complications in critically ill patients with haematological malignancies and are associated with a worsened prognosis. We identified relevant risk factors of bleeding which may prompt closer monitoring or preventive measures.
参考来源
- Vigneron C, Devautour C, Charpentier J, et al. Severe bleeding events among critically ill patients with haematological malignancies. Ann Intensive Care. 2024. PMID: 39373939. doi:10.1186/s13613-024-01383-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。